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Ribozymes have emerged as promising therapeutics for HIV and have been shown to bind and cleave target RNA’s in a 
sequence-specific manner. The HIV-1 regulatory protein tat plays an essential role in the upregulation of viral transcription and 
elongation of viral transcripts, and has therefore been identified as a target for ribozyme studies. To further study the use of 
these reagents, we have designed a number of hammerhead ribozymes targeted to specific sequences within the HIV-1 NL43 tat 
sequence. One of these, Tat5910 and its non-catalytic control Tat5910∆, were cloned into the retroviral vector 
pSuper.retro.neo+GFP (pSRNG) for cell culture studies. Recombinant retrovirus particles were generated by transient 
transfection of 293T cells using a two-plasmid system consisting of the helper plasmid, pPAM3,  and pSRNG5910∆. Identical 
experiments were carried out using two Mo-MLV retroviral vectors, pLNCE, and pLNCLZRz. The resulting recombinant virus 
was used to transduce NIH-3T3 cells, and virus titer (virus particles/ml) was determined from the number of Green Fluorescent 
Protein (GFP)- or β-galactosidase-positive cells. Although producer cells transfected with pSRNG5910∆ expressed GFP, the 
transfection efficieny was low. This resulted in levels of transduced NIH-3T3 cells that were too low to obtain a reliable titer 
measurement. Attempts to optimize titer by increasing the number of transfected producer 293T cells was successful using 
pLNCE and pLNCLZRz. Positive GFP or β-galactosidase expression in NIH-3T3 cells transduced with LNCE and LNCLzRz 
recombinant virus indicated that our two-plasmid virus production system was successful. Extremely low titer along with lower 
cellular expression of GFP suggests that the pSRNG5910 vectors may be better suited to virus production using a stable 
producer cell line such as PA317 
 
Introduction 
Human Immunodeficiency Virus (HIV-1) infection 
results in the gradual loss of TH cells, decreased immune 
competence, and increased susceptibility to various opportunistic 
infections, including Pneumocystis jirovecii pneumonia, 
tuberculosis, and cytomegalovirus. Infection by these 
opportunistic infections, in addition to a TH lymphocyte count 
below 200/mm3
 Traditional HIV treatments have sought to reduce viral 
load by utilizing drugs that prohibit effective viral replication (2). 
For example, Triple Combination Therapy (TCT), which involves 
one protease inhibitor and two reverse transcriptase (RT) 
inhibitors, has been shown to effectively reduce viral load (2). 
Nevertheless, resistance to protease and RT inhibitors have 
already developed, requiring a continued search for therapies that 
can inhibit other HIV gene functions (3). For HIV, these 
functions are generally associated with the six accessory genes 
that control infection and replication: tat, rev, nef,vif, vpr, and vpu 
(4).  
, define the Acquired Immune Deficiency 
Syndrome (AIDS) (1). 
Tat increases viral transcription from the HIV-1 Long 
Terminal Repeat (LTR) by binding to the cis acting RNA 
enhancer element, the transactivation response region (TAR), 
which is transcribed from the R (Repeat) region of the 5’ LTR 
(5). Once transcribed, TAR forms a hairpin loop consisting of a 
base-paired stem, a three nucleotide non-base-paired bulge, and a 
six-nucleotide Guanine-rich loop (2) that is present at the 5’ end 
of all viral transcripts. The Tat/TAR interaction recruits 
numerous cellular transcriptional coactivators to TAR, including 
P-TEFb (Positive Transcription Elongation Factor b), an RNA 
polymerase II C-terminal kinase, resulting in the phosphorylation 
of the C-Terminal Domain (CTD) of RNA Polymerase II (6). The 
phosphorylation of the CTD increases RNA polymerase II 
processivity, thereby inducing elongation of viral transcripts (7).  
Tat is absolutely required for HIV replication and is, therefore, an 
important target for novel anti-HIV reagents. 
Targeting HIV-1 at the genomic level can be 
accomplished by hammerhead ribozymes, which are small 
catalytic RNAs that can be targeted to cleave viral mRNAs (8). 
These RNA enzymes target and cleave mRNA at any XUX’, 
where X is any nucleotide, and X’ is Adenine, Cytosine, or Uracil 
(8). Hammerhead ribozyme design, based on the Hasseloff and 
Gerlach model (9), consists of two flanking regions that provide 
target specificity by Watson-Crick base pairing and a catalytic 
core that cleaves at the target site. Cleavage of tat mRNA 
sequences by hammerhead ribozymes may negatively impact 
transcription initiation and elongation, leading to the inability of 
HIV to replicate within cells (10;11). 
Previously, our lab designed and cloned a number of 
hammerhead ribozymes targeted to the tat genomic sequence of 
the HIV-1 genomic clone NL43. Each of these ribozymes and a 
corresponding non-catalytic control ribozyme was cloned into the 
shuttle vector, pPCR-Script. For initial cell culture testing, 
Tat5910 and its non-catalytic control Tat5910∆, were subcloned 
into the retroviral vector pSuper.Retro.Neo+GFP (pSRNG). This 
modified Moloney Murine Leukemia virus (Mo-MLV) vector can 
infect non-dividing cells (e.g., hematopoietic stem cells) and is 
self-inactivating due to a deletion in the 3’ LTR (12). Importantly 
this vector has been designed to express siRNAs from the RNA 
Polymerase III H1 promoter (13), making it a logical choice for 
expressing other small RNAs such as hammerhead ribozymes. 
For selection purposes pSRNG expresses neomycin 
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phosphotransferase and green fluorescent protein (GFP) from a 
single IRES-containing transcript controlled by the 
phosphoglycerokinase (PGK) promoter (13).  
This paper describes cloning of an anti-HIV 
hammerhead ribozyme Tat5910 into the retroviral vector, 
pSuper.retro.neo+GFP, along with initial cell culture testing. 
These tests involved analysis of transgene expression and 
optimizing virus titer produced in a transient producer cell 
system.  For this we utilized a two-plasmid system consisting of a 
retroviral vector and a helper plasmid (14).  
 
 
Figure 1. Hammerhead ribozyme design. Tat RNA showing the pGUA 
cleavage site at nucleotide 5910 is shown annealed to the ribozyme 
flanking regions. The catalytic core was made inactive by an A to G 
mutation (11). 
Materials and Methods 
Oligonucleotides and cloning 
A hammerhead ribozyme, based on the Haseloff and 
Gerlach model (9) was designed to cleave a pGUA sequence at 
nucleotide 5910 within the HIV genomic clone NL43 (Accession 
number M19921) (Figure 1). The Tat5910 sense (5’-gat ccA 
AGC AAC ACT TTT CTG ATG AGT CCG TGA GGA CGA 
AAC AAT AGC AAT TGG TAC Aa- 3’) and antisense 
sequences (5’-agc ttT GTA CCA ATT GCT ATT GTT TCG 
TCC TCA CGG ACT CAT CAG AAA AGT GTT GCT Tg- 3’) 
were synthesized with BamHI and HindIII sites to facilitate 
cloning. Two-hundred picomoles of each oligonucleotide were 
combined in annealing buffer (100mM NaCl, 50mM HEPES 
buffer (pH 7.4)) and cooled slowly from 90˚C to 4˚C. The 
annealed oligonucleotides were ligated into the BglII and HindIII 
sites of the retroviral vector pSuper.retro.neo+GFP (pSRNG) 
according to the manufacturer’s protocol (Oligoengine). A non-
catalytic ribozyme targeted to the same sequence was created by 
an A to G mutation in the catalytic core. This oligonucleotide was 
synthesized and similarly cloned into pSRNG.  
Ligation was carried out using T4 DNA Ligase 
(Promega) in a 4ºC overnight reaction. The ligated plasmids were 
transformed into JM109 cells and the resulting colonies were 
screened for the presence of the ribozyme. For this, miniprep 
DNA was screened by PCR using a plasmid-specific primer pair 
that framed the cloning site. The PCR reaction consisted of 100 
pMol of each primer and 2X PCR Master Mix (50units/mL Taq 
DNA Polymerase) (Promega). Positive clones were indicated by 
the presence of a 482 bp fragment. Correct ribozyme insertion 
into the resulting plasmids, pSRNG5910 and pSRNG5910∆, was 




Cell lines and transfections 
293T and NIH-3T3 cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% Fetal Bovine Serum (FBS) in a humidified 37°C 
incubator with 5% CO2.  All transfections were done by calcium 
phosphate precipitation based on the method of Berkner and 
Sharp (15). Briefly, 293T cells were plated to 50-70% confluency 
onto 60 mm dishes 24 hours prior to transfection. The cells were 
transiently transfected with 4 µg of plasmid DNA in 125 mM 
CaCl2, and 2X HBS (280 mM NaCl/ 1.5 mM Na2HPO4
 GFP expression was analyzed directly using an 
Olympus CKX41 inverted microscope with epifluorescence. β-
galactosidase expression was measured by the ability to 
metabolize X-gal (10) For this, cells were washed twice with PBS 
and fixed for 15 minutes with 0.1 M Sodium Phosphate, pH 7.0/1 
mM MgCl
/ 50 mM 
HEPES Buffer (pH 7.05)). The resulting precipitate was added to 
the culture medium and allowed to be taken up by the cells. 
Transfection efficiency, as measured by GFP (pLNCE and 
pSRNG5910) or β-galactosidase (pLNCLZRz) expression was 
analyzed as a function of transfection time. For this, 293T cells 
were allowed to remain in contact with the DNA precipitate for 4, 
8, 12, or 24 hours. Transgene expression was assayed 24 hours 
after removal of the DNA precipitate.  
2/0.25%  glutaraldehyde. Subsequently, the cells were 
washed three times with PBS, and stained by the addition of X-
gal (PBS/4 mM K4Fe(CN)6.3H2O/4 mM K3Fe(CN)6,/10 mM 
MgCl2 
 
/0.03% X-gal). The presence of blue-stained cells after 24 
hours indicated positive transfection. 
Recombinant Virus Production  
Recombinant viruses were produced in 293T cells 
using a transient two-plasmid system consisting of a retroviral 
vector and a helper plasmid (10;14). Three retroviruses were 
analyzed for their ability to generate retroviruses in this system: 
pSRNG5910∆, pLNCE, and pLNCLzRz. All are Mo-MLV 
viruses that express either GFP (pSRNG5910∆, pLNCE) or β-
galactosidase (pLNCLzRz). pPAM3 is a Mo-MLV based helper 
plasmid that expresses all retroviral structural genes, including an 
amphotropic glycoprotein (16).  
To generate recombinant retrovirus particles for 
transduction into target cells, 0.5 x 106 293T cells were plated 
onto 60mm dishes. After 24 hours, these cells were transfected as 
described using 4 µg helper plasmid (pPAM3) and 4 µg retroviral 
vector (pSRNG5910∆, pLNCE, or  pLNCLZRz). The resulting 
precipitate was allowed to be taken up by the cells from 4 to 24 
hours, after which time the medium was replaced. Twenty-four 
hours later, the virus-containing medium was harvested from the 
producer cells, filtered through a 0.45 µm syringe filter, and 
stored at -
The presence of virus particles in the harvested medium 
was determined following transduction of target cells. For this, 
0.25 x 10
80ºC.  
6 NIH-3T3 cells were plated onto 35mm dishes. After 
24 hours, these cells were transduced by the addition of one 
milliliter each of harvested medium and fresh culture medium 
containing 8 µg polybrene (4 µg/ml). The cells and virus particles 
were incubated together for 24 hours, after which the medium 
was replaced. After an additional 24 hours, virus titer was 
 
 Journal of the South Carolina Academy of Science, [2009], 7(2) 20 
determined from the number of GFP or X-gal positive cells. 
Virus titer was determined from the average number of positive 
target cells in 10-20 randomly chosen fields at 200X using bright-
field or epifluorescence microscopy. This number was 
extrapolated to determine the total number of positive cells.    
 
Optimizing virus titer 
Transfection incubation time, referring to the length of 
time the transfection reagent remained on producer cells, was 
altered to optimize virus titer. 293T cells were incubated with 
DNA precipitate at four different time points: 4, 8, 12, and 24 
hours. After each time point, the medium was replaced and the 
cells incubated for an additional 24 hours. The virus containing 
medium was harvested and used to transduce NIH-3T3 cells as 
described. GFP or β-galactosidase expression was monitored, and 




The HIV-1 NL43 genomic sequence was analyzed for 
the presence of potential hammerhead ribozyme target sites. One 
site, a pGUA located at nucleotide 5910 was used to design an 
anti-tat hammerhead ribozyme. This ribozyme and its non-
catalytic control (Figure 1) were synthesized and cloned into the 
retroviral vector, pSuper.retro.neo+GFP. Sequencing was used to 
verify the ribozyme sequence in each of the resulting plasmids: 
pSRNG5910 and pSRNG5910∆ (Figure 2). Once cloned,  
 
 
Figure 2. Retroviral vector pSRNG5910. Tat5910 oligonucleotides were 
synthesized and cloned into the BglII and HindIII sites of 
pSuper.retro.neo+GFP. The resulting vector is shown. A similar vector, 
pSRND5910∆, was created by cloning the non-catalytic version of the 
ribozyme. 
pSRNG5910∆ was tested to ensure GFP expression was not 
affected by the cloning process. 293T cells were transiently 
transfected using the calcium phosphate method and after 48 
hours analyzed for transgene expression. These results indicated 
relatively high levels of GFP expression (Figure 3). However, 
GFP levels were noticeably lower than in cells transfected in 
parallel with pLNCE (data not shown).    
 
 
Figure 3. GFP expression. 293T cells were transfected with 
pSRNG5910∆ by calcium phosphate precipitation. GFP expression was 
monitored 48 hours later. 
The ability to generate recombinant retroviral particles 
in a transient transfection system was next investigated using a 
retroviral vector (pSRNG5910∆, pLNCE, or pLNCLZRz) and a 
helper plasmid (pPAM3) to produce viral particles in 293T cells. 
Forty-eight hours after transfection, the virus-containing medium 
was harvested and used to transduce NIH-3T3 cells. The producer 
and target cells were analyzed for either GFP or β-galactosidase 
expression (Figure 4) as a measure of transfection (293T cells) or 
transduction (NIH-3T3 cells). In these tests, virus production was 
observed using both pLNCE and pLNCLZRz. However virus 
production using the pSRNG5910D vector was not observed in 
this series of experiments (Figure 4). 
 
 
Figure 4. Production of recombinant retrovirus. 293T cells were 
transiently transfected with pPAM3 and one of three retroviral vectors. 
Transfection efficiency was determined by the relative number of GFP- or 
X-gal positive cells (Upper panels). Virus containing medium was 
harvested and used to transduce NIH-3T3 cells. Virus-mediated 
expression was only evident in pLNCE and pLNCLZRz  transduced cells 
(Lower panels). GFP-positive cells are green. X-gal positive cells are 
blue. 
To optimize virus titer, the length of transfection 
incubation period, as measured by the time the DNA precipitate 
was incubated with the 293T cells, was altered. For this, the 
transfection reagent was left on the 293T cells for 4, 8, 12, or 24 
hours. The precipitate was removed by a change of medium and 
24 hours later, virus was harvested in the culture medium. At this 
time the 293T producer cells were analyzed for GFP or β-
galactosidase expression to make sure the transfection was 
successful. Regardless of the transfection incubation period, all 
293T transfection experiments yielded positive GFP or β-
galactosidase expression. For the retroviral vector pSRNG5910∆, 
higher GFP expression was observed in the 12 hour incubation 
period compared to the four and eight hour periods.  However, no 
visible differences were evident in GFP expression among the 12 
and 24 hour incubation periods (data not shown). 
pLNCE pLNCLZRz pSRNG5910∆
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The ultimate purpose of these transfection studies was 
to determine if virus production was increased by allowing the 
293T producer cells to remain in contact with the transfection 
reagents for longer periods of time. To determine the virus titer 
produced in these experiments, NIH-3T3 cells were incubated 
with virus-containing medium harvested from the producer cells. 
With regards to virus production, extremely low levels of GFP 
expression was observed in the NIH-3T3 cells transduced with 
the harvested medium from producer cells transfected with 
pPAM3 and pSRNG5910∆. This was true of all incubation 
periods, and resulted in an inability to determine a reliable titer 
for this vector (Figure 4). On the other hand, with the exception 
of the eight hour incubation period, recombinant virus was 
produced in target cells transduced with pLNCE or pLNCLZRz, 
as measured by the number of GFP or X-gal positive cells (Figure 
5). Analysis of virus titer generated by pLNCLZRz transfections 
for all incubation periods indicated an increase over time. The 
maximum titer obtained with this vector was measured at the 24 
hour time point as 1 x 104
 
 virus particles per milliliter (Figure 5). 
The virus titer produced using pLNCE indicated a large increase 
at the 12 hour time point; however, the titer at the 24 hour time 
point was approximately 50% less (Figure 5). At all time points 
tested, the pSRNG5910D vector failed to produce a measurable 
titer. 
Figure 5. Optimization of virus titer. The number of virus particles per 
milliliter of harvested culture medium was determined for pLNCE and 
pLNCLZRz transduced NIH-3T3 cells. Virus titer was optimized by 
increasing the transfection incubation tome from 4 to 24 hours. Virus titer 
was found to be directly related to this increase.  
Conclusions 
Previous studies have shown that hammerhead 
ribozymes targeted to HIV-1 accessory genes such as tat can 
down regulate virus replication. Many of these studies have used 
retroviral vectors to express ribozymes as part of an RNA 
Polymerase II transcript (10;11). While effective, these 
transcripts are often large and likely produce secondary structures 
that may interfere with efficient ribozyme cleavage. The pSUPER 
family of vectors were specifically created to express siRNAs 
from the RNA Polymerase I H1 promoter and should represent a 
good choice to express hammerhead ribozymes. Additionally, the 
pSUPER retroviral vectors are self-inactivating and express 
neomycin phosphotransferase and GFP from the PGK promoter. 
The primary goal of this project was to clone a 
hammerhead ribozyme targeted to HIV-1 tat into pSRNG and to 
characterize the resulting vector prior to its use in anti-HIV 
experiments. A second goal was to determine the optimal 
conditions to produce recombinant retrovirus particles in a 
transient two-plasmid system. The resulting plasmids, 
pSRNG5910 and pSRNG5910∆ were generated for this purpose. 
Initial tests indicated that both retroviral vectors expressed GFP 
when transiently transfected into 293T cells. However, in all 
cases the non-pSUPER retrovirus, pLNCE, generated greater 
GFP expression than either pSRNG5910 or pSRNG5910∆ in 
transfected 293T cells. Although it does not explain the overall 
lower transfection efficiency of pSRNG5910∆, it is likely that 
pLNCE generated greater levels of GFP expression due to 
transcriptional control of the immediate early CMV promoter. In 
comparison, GFP expression in the pSUPER vector is controlled 
by the comparatively weaker PGK promoter. In fact, a number of 
cells transfected with pSRNG5910∆ appeared to be very weakly 
positive for GFP expression, although they were not counted as 
GFP-positive for these studies. The other retrovial vector used in 
these experiments, pLNCLZRz also yielded higher numbers of 
transfected cells, and like pLNCE, this plasmid possesses a CMV 
promoter that controls expression of β-galactosidase. 
The use of these plasmids as retroviral vectors was next 
studied by comparing the ability of pSRNG5910∆ to produce 
virus with the retroviral vectors pLNCE and pLNCLZRz. In these 
studies, pSRNG5910∆ failed to produce measurable virus. 
Although a very small number of GFP-positive target cells were 
identified, the number was too small to determine a reliable titer. 
Subsequently, the length of transfection incubation period was 
altered in an attempt to optimize virus titer. Transfection with the 
helper plasmid, pPAM3, and either pLNCE or pLNCLZRz 
produced measurable virus titers, up to a high of 104
It is quite possible that the two different ways virus 
expression was measured and used to determine titer played a 
role in the discrepancies seen in the virus titer optimization 
experiments (Figure 5). Target cells transduced with recombinant 
virus produced using the pLNCLZRz vector resulted in the ability 
to metabolize X-gal.; therefore staining produced blue cells that 
were easy to identify and count using brightfield microscopy. 
There is a higher degree of uncertainty involved in scoring GFP-
positive cells produced from transduction with recombinant virus 
from pLNCE and pSRNG5910∆. It may be that when using these 
vectors, a more reliable way of determining titer would be to 
generate neomycin resistant colonies.  
 particles per 
milliliter. Again, pSRNG5910∆ failed to produce measurable 
virus titers in these experiments. Overall; however, these result 
did indicate that our two-plasmid system successfully generated 
recombinant virus. 
Ultimately, because pSRNG5910∆ failed to generate 
measurable levels of recombinant virus, optimization studies will 
be impractical until a method for producing virus with this vector 
can be developed. Although transient systems may be 
successfully used to generate virus using pSRNG-based vectors, 
future studies will need to increase transfection efficiency. One 
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procedures. Alternatively, it may be necessary to generate a stable 
producer line for efficient virus production.  
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